Marius Gradianu, DO
Ophthalmology · Elmhurst, ILNPI 1144665878
Payments from drug & device makers
Across 645 payments — averaging $64.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$6K
- Carl Zeiss Meditec USA, Inc.$5K
- Bausch & Lomb Americas Inc.$5K
- Johnson & Johnson Surgical Vision, Inc.$4K
- AbbVie$3K
- Biotissue Holdings Inc.$2K
- plus $16K from 37 others
What the payments were for
- Consulting fees$6902%
- Travel & lodging$6,09715%
- Food & beverage$30,58173%
- Entertainment$380%
- Other$4,23210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMERA 700$3,435
- Tecnis 1-piece IOL$2,504
- Tecnis 3-piece IOL$2,504
- Tecnis Symphony IOL$2,504
- Tecnis Symphony Toric IOL$2,504
- STELLARIS ELITE$1,994
- enVista Aspire IOL$1,139
- TENEO$1,139
- iDoseTR$1,134
- enVista MX60 IOL$1,096
- XEN GLAUCOMA TREATMENT SYSTEM$1,086
- STELLARIS$1,078
- CE-marked KXLA system$1,042
- IC-8 Apthera IOL$980
- IOLMaster 700$928
- XIIDRA$811
- Hydrus Microstent$755
- MIEBO$750
- TEPEZZA$618
- Prokera$506
How this compares
$41,638 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 34 | $45,269 |
| CequaCyclosporine | 36 | $37,189 |
| LumiganBimatoprost | 61 | $33,417 |
| VevyeCyclosporine | 32 | $27,880 |
| RestasisCyclosporine | 26 | $26,807 |
| Prednisolone Acetate | 519 | $22,846 |
| XdemvyLotilaner | 12 | $22,291 |
| RocklatanNetarsudil Mesylat/Latanoprost | 35 | $15,970 |
| ProlensaBromfenac Sodium | 17 | $7,342 |
| Difluprednate | 51 | $6,939 |
| MoxifloxacinMoxifloxacin Hcl | 302 | $5,778 |
| Ketorolac Tromethamine | 336 | $5,322 |
| RhopressaNetarsudil Mesylate | 13 | $5,235 |
| VyzultaLatanoprostene Bunod | 11 | $4,794 |
| Bromfenac Sodium | 21 | $3,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $2,746 | $60,22487 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $4,813 | $50,06345 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,312 | $37,18936 claims |
| Harrow Eye, LLCVevye | $390 | $27,88032 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $338 | $22,29112 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $27 | $21,20548 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $1,964 | $7,34217 claims |
| AlconSimbrinza | $2,299 | $3,57318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Elmhurst
- Mateen AliniazeeElmhurst$122K
- Kevin KovachElmhurst$84K
- Saad AhmadElmhurst$64K
- Donald SandersElmhurst$62K
- Veeral ShethOak Forest$14.8M
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.9M
- Manjot GillChicago$1.4M
- Mitchell JacksonLake Villa$1.4M
- Ramanath BhandariSpringfield$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.